TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00815178

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: For Inspiratory muscle training (IMT)patients carried out the IMT on a daily basis for eight weeks, with duration of 30 minutes and intensity corresponding to 30% of resting PImax, with a linear pressure resistance device (Threshold®). Weekly maximum inspiratory pressure (PImax) evaluations and workload adjustments were performed. Inspiratory load was adjusted on a weekly basis to maintain 30% of the subject's PImax. Training sessions were carried out at home for both groups and supervised once a week at the hospital.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Inpiratory muscle training placebo
Description: Inspiratory muscle training was carried out on the same basis as in the intervention group but with no inspiratory load.
Study: NCT04404218

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Açaí palm berry extract - natural product
Description: Patients will be prescribed to take 1 capsule (520mg) of Açaí Palm Berry every 8 hours for a total of 3 capsules a day, during 30 days. Total dose: 1,560mg/day of Açaí Berry extract.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will take 1 placebo pill every 8 hours (total of 3 capsules a day) for 30 days.
Study: NCT04565327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized Carbon C 13 Pyruvate
Description: Given IV prior to imaging

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized Carbon C 13 Pyruvate
Description: Given IV prior to imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: Undergo MRI
Study: NCT00558688

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy
Description: Photodynamic therapy applied to actinic keratoses

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy
Description: Photodynamic therapy applied to actinic keratoses
Study: NCT05319938

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CAF only
Description: After local anesthesia, initially, sulcular incisions were made on the buccal aspect of the teeth and two vertical incisions were made. A trapezoidal flap was elevated with a split-full-split approach in the coronal-apical direction. The anatomic inter-dental papillae adjacent to the involved tooth were de-epithelialized. Plaque, calculus, and soft tooth structures on exposed root surfaces were removed with curettes. No further mechanical or chemical root conditioning materials were performed. The flap was coronally placed over the membranes to completely cover the CEJ and sutured with 6.0 propylene suture.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CAF+CGF
Description: After local anesthesia, initially, sulcular incisions were made on the buccal aspect of the teeth and two vertical incisions were made. A trapezoidal flap was elevated with a split-full-split approach in the coronal-apical direction. The anatomic inter-dental papillae adjacent to the involved tooth were de-epithelialized. Plaque, calculus, and soft tooth structures on exposed root surfaces were removed with curettes. No further mechanical or chemical root conditioning materials were performed. The flap was coronally placed over the membranes to completely cover the CEJ and sutured with 6.0 propylene suture.~Blood samples were collected into 10 ml glass-coated plastic tubes without anticoagulant solutions. These tubes were placed into CGF centrifuge machine and centrifuged immediately . CGF membrane were placed over the defect. The flap was coronally placed over the membranes to completely cover the CEJ and sutured with 6.0 propylene suture.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CAF+A-PRF
Description: After local anesthesia, initially, sulcular incisions were made on the buccal aspect of the teeth and two vertical incisions were made. A trapezoidal flap was elevated with a split-full-split approach in the coronal-apical direction. The anatomic inter-dental papillae adjacent to the involved tooth were de-epithelialized. Plaque, calculus, and soft tooth structures on exposed root surfaces were removed with curettes. No further mechanical or chemical root conditioning materials were performed. The flap was coronally placed over the membranes to completely cover the CEJ and sutured with 6.0 propylene suture.~Blood samples were collected into 10 ml glass-coated plastic tubes without anticoagulant solutions. These tubes were placed into A-PRF centrifuge machine and centrifuged immediately. A-PRF membrane were placed over the defect. The flap was coronally placed over the membranes to completely cover the CEJ and sutured with 6.0 propylene suture.
Study: NCT04041843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Apixaban 10 mg twice daily p.o. for seven days followed by 5 mg twice daily p.o. for children and adolescents weighting ≥40 kg
Study: NCT03326271

Intervention type: PROCEDURE
Intervention: Exeter stem
Description: Patients treated with an total or hemiarthroplasty using a Exeter stem for a displaced femoral neck fracture

Intervention type: PROCEDURE
Intervention: Lubinus SP2 stem
Description: Patients treated with an total or hemiarthroplasty using a SP2stem for a displaced femoral neck fracture
Study: NCT01880593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium
Description: Subjects in this arm take 600-1200mg of Lithium pills at night for duration of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects in this arm take placebo pills at night for duration of the study.
Study: NCT00889109

Intervention type: OTHER
Intervention: Three dimensional unrestricted arm movements
Description: The subjects will carry out three dimensional unrestricted arm movements. The subjects' movements will be recorded by optoelectronic infrared cameras and software. Assessment of smoothness parameters of subjects' movements will allow discriminating between subjects with intact or impaired proprioception.

Intervention type: OTHER
Intervention: Three dimensional unrestricted arm movements
Description: The subjects will carry out three dimensional unrestricted arm movements. The subjects' movements will be recorded by optoelectronic infrared cameras and software. Assessment of smoothness parameters of subjects' movements will allow discriminating between subjects with intact or impaired proprioception.

Intervention type: OTHER
Intervention: Three dimensional unrestricted arm movements
Description: The subjects will carry out three dimensional unrestricted arm movements. The subjects' movements will be recorded by optoelectronic infrared cameras and software. Assessment of smoothness parameters of subjects' movements will allow discriminating between subjects with intact or impaired proprioception.
Study: NCT02512627

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive training
Description: visuospatial, attention, memory, and executive abilities

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: visuospatial, attention, memory, and executive abilities
Study: NCT01759901

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pringle
Description: Vascular clamp is applied across hepatoduodenal ligament intermittently in 15 minutes on / 5 minutes off interval
Study: NCT02683083

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: [131I]-SGMIB Anti-HER2 VHH1
Study: NCT02623543

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: OrthoK

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OrthoK
Study: NCT01552447

Intervention type: OTHER
Group type: OTHER
Intervention: EpiFix
Description: Dehydrated placental tissue

Intervention type: OTHER
Group type: OTHER
Intervention: EpiFix
Description: Dehydrated placental tissue
Study: NCT02512627

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: visuospatial, attention, memory, and executive abilities

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: endurance, balance, and mobility

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical exercise
Description: endurance, balance, and mobility

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: endurance, balance, and mobility
Study: NCT00562666

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: T gamma delta lymphocytes
Description: Single hepatic intra arterial administration of increasing doses of T gamma delta lymphocytes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: T gamma delta lymphocytes
Description: Single hepatic intra arterial administration of increasing doses of T gamma delta lymphocytes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: T gamma delta lymphocytes
Description: Single hepatic intra arterial administration of increasing doses of T gamma delta lymphocytes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: T gamma delta lymphocytes
Description: Single hepatic intra arterial administration of increasing doses of T gamma delta lymphocytes
Study: NCT02723071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Participants will receive a total of 8 intravenous (IV) infusions of ocrelizumab given at intervals of 3 weeks, until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Participants will receive a total of 8 intravenous (IV) infusions of ocrelizumab given at intervals of 3 weeks, until disease progression or unacceptable toxicity.
Study: NCT01552447

Intervention type: OTHER
Group type: OTHER
Intervention: Compression Therapy
Description: Compression bandaging

Intervention type: OTHER
Group type: OTHER
Intervention: Compression Therapy
Description: Compression bandaging

Intervention type: OTHER
Group type: OTHER
Intervention: Compression Therapy
Description: Compression bandaging
Study: NCT04274686

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tegaderm placement
Description: Placement of perforated Tegaderm bandage over lower face, with diamond-shaped hole aligned with the patient's mouth, for use during bag-mask ventilation
Study: NCT02723071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Participants will receive a total of 8 intravenous (IV) infusions of ocrelizumab given at intervals of 3 weeks, until disease progression or unacceptable toxicity.
Study: NCT04274686

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Tegaderm
Description: Bag-mask ventilation performed in ordinary fashion, without use of Tegaderm bandage
Study: NCT02639741

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: Preoperative melatonin tablet will be given and postoperative pain scores will be evaluated

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Melatonin
Description: Preoperative melatonin tablet will be given and postoperative pain scores will be evaluated

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: Preoperative melatonin tablet will be given and postoperative pain scores will be evaluated

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C
Description: Preoperative vitamin C tablet will be given and postoperative pain scores will be evaluated

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin C
Description: Preoperative vitamin C tablet will be given and postoperative pain scores will be evaluated

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C
Description: Preoperative vitamin C tablet will be given and postoperative pain scores will be evaluated

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Preoperative placebo tablet will be given and postoperative pain scores will be evaluated

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Preoperative placebo tablet will be given and postoperative pain scores will be evaluated

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Preoperative placebo tablet will be given and postoperative pain scores will be evaluated
Study: NCT01852617

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training in smoking cessation counseling
Description: Midwife facilitators in the intervention clinics will be identified and trained to deliver the 5 A's to pregnant women and will then disseminate and implement the program. The 5 A's (Ask, Advise, Assess, Assist, Arrange) is a strategy consisting of a brief cessation counseling session of 5-15 minutes delivered by a trained provider, which is considered the standard of care worldwide
Study: NCT03469505

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: COPES
Description: Cooperative Pain Education and Self-Management for chronic pain therapy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT-CP
Description: Cognitive Behavioral Therapy for Chronic Pain
Study: NCT03003871

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Powered toothbrush
Description: Oral-B® AdvancePowerTM 400 series

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual toothbrush
Description: Oral-B® Pro-Health All-In-One

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Toothpaste
Description: Colgate Maximum Cavity Protection®
Study: NCT02506985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rivaroxaban
Description: Immediately following completion of alteplase infusion, patients will receive rivaroxaban 15 mg oral bid for 21 days followed by 20 mg oral daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: warfarin
Description: Immediately following completion of alteplase infusion, patients will continue on unfractionated heparin or low-molecular weight heparin with initiation of warfarin adjusted to INR of 2-3.
Study: NCT03003871

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Toothpaste
Description: Colgate Maximum Cavity Protection®

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine gluconate mouth rinse
Description: CorsodylPTMP
Study: NCT00517530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab was provided in single-dose glass vials as a freeze-dried powder.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab was provided in single-dose glass vials as a freeze-dried powder.
Study: NCT06449365

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: midazolam by nasal atomizer
Description: midazolam

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous midazolam
Description: midazolam
Study: NCT02835053

Intervention type: OTHER
Intervention: Frailty
Description: Participants will be defined as frail based on the Johns Hopkins ACG Frailty Defining Diagnoses Indicator, which will be applied to available health administrative data in the 3 years preceding index hospital admission. If no frailty defining diagnoses are present participants will be defined as not frail
Study: NCT01373671

Intervention type: DEVICE
Group type: OTHER
Intervention: SIEMENS INSPIRATION DIGITAL BREAST TOMOSYNTHESIS (DBT) SYSTEM
Description: DBT scan
Study: NCT00338975

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Social Skills Training (CBSST)
Description: There are 36 weekly group sessions, each session is 2 hours in length, with a half-hour break after the first hour. The intervention integrates CBT and SST techniques and neurocognitive compensatory aids. All participants are asked to identify a goal. The SST components are based, in part, on a pre-packaged SST intervention available from Psychiatric Rehabilitation Consultants. The CBT components are based on techniques developed for CBT in general and techniques developed specifically for patients with schizophrenia. Cognitive therapy is combined with role-play practice of communication skills and problem-solving training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Goal-focused supportive contact (GFSC)
Description: There are 36 weekly group sessions, each 2 hours in length, with a half-hour break after the first hour. GFSC has a number of specific goals and interventions, including providing a safe environment where the patient can discuss her/his feelings and concerns; to validate these feelings and concerns; and to provide support and guidance to the client so that she/he can make progress to solving problems or alleviating concerns and worries. Psychotic symptoms and cognition are not directly targeted. Therapists utilize non-specific therapeutic techniques, including providing unconditional positive regard, reflective listening, encouraging, paraphrasing, and summarizing. Therapists do not develop a formulation or teach skills.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Skills Training
Description: The SST components are based, in part, on a pre-packaged SST intervention available from Psychiatric Rehabilitation Consultants. Participants engage in role plays and problem solving.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal Setting
Description: All participants are asked to identify a personally meaningful goal as soon as possible in therapy. Over the 36 weeks, participants in CBSST learn skills related to goal attainment, while participants in GFSC do not receive skills aimed at goal attainment, but are encouraged to discuss their goals .

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Goal Setting
Description: All participants are asked to identify a personally meaningful goal as soon as possible in therapy. Over the 36 weeks, participants in CBSST learn skills related to goal attainment, while participants in GFSC do not receive skills aimed at goal attainment, but are encouraged to discuss their goals .
Study: NCT04095767

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurothrombectomy
Description: Intra-arterial recanalization therapy or mechanical thrombectomy (MT) is a therapeutic option for patients who are not candidates for t-PA or in whom t-PA has failed. MT is performed by means of various devices (Merci Revive, Penumbra, etc.). There are currently two major approaches to MT: the so-called stent retrievers (used with or without a balloon catheter), and catheters used for direct aspiration (manual with syringe or by aspiration pump via distal access catheters \[DACs\]). Moreover, both techniques can be combined. MT may be performed following IV t-PA, as a stand alone therapy, or in conjunction with IA thrombolysis.
Study: NCT03679325

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamine D
Description: a dose once a week

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: whole body vibration (WBV)
Description: 03 months of WBV training three times per week

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: whole body vibration (WBV)
Description: 03 months of WBV training three times per week
Study: NCT03291561

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: Acupuncture at Baihui, Nei guan, bilateral Zu sanli and bilateral Tian shu.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham electroacupuncture
Description: Sham acupuncture at Baihui, Nei guan, bilateral Zu sanli and bilateral Tian shu.
Study: NCT01437787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR302503
Description: Pharmaceutical form:capsule~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR302503
Description: Pharmaceutical form:capsule~Route of administration: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form:capsule~Route of administration: oral
Study: NCT00517530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab was provided in single-dose glass vials as a freeze-dried powder.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab was provided in single-dose glass vials as a freeze-dried powder.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab was provided in single-dose glass vials as a freeze-dried powder.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab was provided in single-dose glass vials as a freeze-dried powder.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab was provided in single-dose glass vials as a freeze-dried powder.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab was provided in single-dose glass vials as a freeze-dried powder.
Study: NCT01029522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin (Lipilou)
Description: treatment of dyslipidemia administration : PO, qod

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin (Lipitor)
Description: treatment of dyslipidemia administration : PO, qod
Study: NCT01386593

Intervention type: DRUG
Group type: OTHER
Intervention: Basel cocktail+(Fluconazole, Ciprofloxacin, Paroxetine)

Intervention type: DRUG
Group type: OTHER
Intervention: Basel Cocktail

Intervention type: DRUG
Group type: OTHER
Intervention: Basel cocktail + Rifampicin
Study: NCT02494544

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Off the Shelf Total Knee Replacement
Description: A knee replacement system by DePuy, Zimmer, Biomet, Smith \& Nephew, or Stryker

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Off the Shelf Total Knee Replacement
Description: A knee replacement system by DePuy, Zimmer, Biomet, Smith \& Nephew, or Stryker

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Off the Shelf Total Knee Replacement
Description: A knee replacement system by DePuy, Zimmer, Biomet, Smith \& Nephew, or Stryker
Study: NCT00281658

Intervention type: DRUG
Group type: OTHER
Intervention: Lapatinib (GW572016) oral tablets
Description: 1500 mg oral daily continuously

Intervention type: DRUG
Group type: OTHER
Intervention: Lapatinib (GW572016) oral tablets
Description: 1500 mg oral daily continuously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib (GW572016) oral tablets
Description: 1500 mg oral daily continuously

Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel infusion
Description: Paclitaxel 80 mg/m2 every 3 weeks, 4th week rest for minimum 6 months